Ph-positive ALL
Ph-positive ALL is acute lymphoblastic leukaemia carrying the Philadelphia chromosome. It was once the worst kind and is now often the best-controlled, thanks to TKIs and blinatumomab.
BCR::ABL1-positive B-ALL, ~25% of adult B-ALL and rising with age. TKI (dasatinib or ponatinib) plus reduced-intensity chemotherapy or steroids alone induces remission in nearly all; PhALLCON showed ponatinib beats imatinib for MRD-negative remission (34.4% vs 16.7%); D-ALBA showed a chemotherapy-free dasatinib-blinatumomab regimen with 95% 18-month survival. Whether transplant in first remission is still needed for MRD-negative patients is the open question.
Pages like this
not linked directly; found by shared links- TermPhiladelphia chromosome (Ph+, BCR::ABL1)
Shares Asciminib, Ponatinib, Dasatinib, Blinatumomab.
- Key paperIRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia
Shares Asciminib, Dasatinib, BCR::ABL1 (Philadelphia chromosome), Imatinib.
- InstitutionGIMEMA
Shares D-ALBA (GIMEMA LAL2116), Blinatumomab, Imatinib, Acute lymphoblastic leukaemia.
- TermMolecular response (MMR, MR4, treatment-free remission)
- PersonHagop M. Kantarjian
Shares Blinatumomab, Imatinib, Acute lymphoblastic leukaemia.
- CancerChronic myeloid leukaemia (CML)
Shares Asciminib, Ponatinib, Dasatinib, BCR::ABL1 (Philadelphia chromosome).
- TermOn-target resistance mutations (gatekeeper, solvent-front, compound)
- Key paperFirst imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia